Concomitant Monitoring ofWT1andFLT3-ITDexpression inFLT3-ITDacute Myeloid Leukemia Patients: Which Should We Trust as a Minimal Residual Disease Marker?
American Journal of Hematology - United States
doi 10.1002/ajh.24686
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 22, 2017
Authors
Publisher
Wiley